Papillomavirus vaccines

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8420103
APP PUB NO 20100143408A1
SERIAL NO

12449197

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A nucleic acid molecule encoding at least one papillomavirus E2 polypeptide, or a vector, an infectious viral particle or a therapeutic composition thereof is formulated into a drug product useful for treating a patient suffering from a persistent papillomavirus infection caused by at least one papillomavirus; particular such vectors are nucleic acid molecules containing a first nucleotide sequence encoding a papillomavirus E1 polypeptide and a second nucleotide sequence encoding a papillomavirus E2 polypeptide wherein the 3′ portion of the first nucleotide which in the natural content is 100% identical to the 5′ portion of the second nucleotide is modified so as to exhibit a percentage of identity between said portions of at most 75%.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • TRANSGENE S.A.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Balloul, Jean-Marc Strasbourg, FR 15 71
Baudin, Martine Caluire, FR 1 4
Silvestre, Nathalie Ergersheim, FR 27 82

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 16, 2024
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00